An in-Silico study – Targeting a Genetic Intellectually Different ability’s Therapy, through Phytochemicals

Abstract

People with ‘intellectually different ability or intellectual disability (ID)’ have neurodevelopmental deficits, which is shown by, limitations in ‘intellectual functioning’ and ‘adaptive behavior’. ‘Fragile X syndrome’ is the common genetic cause of ‘Intellectually different ability (ID)’. Therefore in this in-silico research, a protein named ‘mGluR5’ was targeted for the therapy of ID in Fragile X Syndrome. In Fragile X syndrome, due to mutation in FMR1 gene, there’s lack of FMRP (Fragile X Mental Retardation Protein), resulting in unimpeded (lack of inhibition by FMRP) activity of ‘mGluR5’, which leads to aberrant dendritic development with mis-signalling, This results in ID, Autism and Psychopathology. As an attempt, for overcoming this problem of ID seen in the patients of Fragile X syndrome, in this research, ‘mGluR5’ was targeted by 19 different phytochemicals, collected from IMPPAT 2.0 databse. This study was done with the aid of multiple bioinformatics tools and biological databses, namely ‘RCSB-PDB’, ‘BIOVIA Discovery Studio’, ‘PubChem’, ‘CACTUS Online SMILES translator’, ‘CB-Dock’ and ‘pkCSM’. The conclusion of this research, compared with ‘Fenobam (already reported against mGluR5) was that, ‘beta-Bisabolene’ and ‘Cirisilineol’ have relatively more probability to serve as therapeutic compounds against ‘mGluR5’, as compared to ‘‘Platainoside-B’, ‘Orientin’ and other phytochemicals in the list of 19 phytochemicals studied in this research. However, different results may or may not show up in ‘in-vitro’ or ‘in-vivo’ researches.